This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Powerful perspectives
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Data & publication
Pancreatic CAF-derived Autotaxin (ATX) drives autocrine CTGF expression to modulate pro-tumorigenic signaling
Press coverage
Drug Target Review – Biotech leader champions targeted cancer treatments and diversity
Data & publication
High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma
Data & publication
Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Press coverage
MedNous – Small company, big theme: How iOnctura is pursuing drug resistance
Press release
iOnctura announces expansion of roginolisib clinical trial program to NSCLC
Press coverage
Endpoints News – iOnctura raises €80M to advance early-stage rare eye cancer treatment
Press coverage
FirstWord Pharma – With fresh €80M in hand, iOnctura looks to chart new PI3K path
Press release
€80 million Series B financing to progress pipeline through Phase II trials
Data & publication
Roginolisib: an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3kδ) in patients with uveal melanoma and advanced cancers
Press release
US FDA grants orphan drug designation for iOnctura’s first-in-class autotaxin cancer therapy
Data & publication
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
Looking for media
resources?